New York, NY (June 27, 2011) - The new label for the use of erythropoiesis-stimulating agents (ESAs), is consistent with the National Kidney Foundation's position that medical decisions of all kinds should be made jointly by the patient and the health care professional who is managing his or her care, taking into account the latest and most credible information about risks and benefits. These include the impact on candidacy for transplant and the difference between anemia therapy for individuals on dialysis and people in other stages of chronic kidney disease.
African Americans & Kidney Disease
Did you know that African Americans are 3 times more likely to experience kidney failure? Because kidney disease often has no symptoms, it can go unnoticed until it is very advanced. But there's good news. Taking steps to live a healthy lifestyle can go a long way towards reducing risk. Read more.